158 related articles for article (PubMed ID: 15070703)
1. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera.
Huang G; Shigesada K; Wee HJ; Liu PP; Osato M; Ito Y
Blood; 2004 Apr; 103(8):3200-7. PubMed ID: 15070703
[TBL] [Abstract][Full Text] [Related]
2. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.
Durst KL; Lutterbach B; Kummalue T; Friedman AD; Hiebert SW
Mol Cell Biol; 2003 Jan; 23(2):607-19. PubMed ID: 12509458
[TBL] [Abstract][Full Text] [Related]
3. Core-binding factor beta (CBFbeta), but not CBFbeta-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFbeta-deficient embryonic stem cells.
Miller JD; Stacy T; Liu PP; Speck NA
Blood; 2001 Apr; 97(8):2248-56. PubMed ID: 11290585
[TBL] [Abstract][Full Text] [Related]
4. Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation.
Huang G; Shigesada K; Ito K; Wee HJ; Yokomizo T; Ito Y
EMBO J; 2001 Feb; 20(4):723-33. PubMed ID: 11179217
[TBL] [Abstract][Full Text] [Related]
5. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
[TBL] [Abstract][Full Text] [Related]
6. The PEBP2beta/CBF beta-SMMHC chimeric protein is localized both in the cell membrane and nuclear subfractions of leukemic cells carrying chromosomal inversion 16.
Kanto S; Chiba N; Tanaka Y; Fujita S; Endo M; Kamada N; Yoshikawa K; Fukuzaki A; Orikasa S; Watanabe T; Satake M
Leukemia; 2000 Jul; 14(7):1253-9. PubMed ID: 10914550
[TBL] [Abstract][Full Text] [Related]
7. Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis.
Lukasik SM; Zhang L; Corpora T; Tomanicek S; Li Y; Kundu M; Hartman K; Liu PP; Laue TM; Biltonen RL; Speck NA; Bushweller JH
Nat Struct Biol; 2002 Sep; 9(9):674-9. PubMed ID: 12172539
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation.
Kanno Y; Kanno T; Sakakura C; Bae SC; Ito Y
Mol Cell Biol; 1998 Jul; 18(7):4252-61. PubMed ID: 9632809
[TBL] [Abstract][Full Text] [Related]
9. Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.
Kummalue T; Lou J; Friedman AD
Mol Cell Biol; 2002 Dec; 22(23):8278-91. PubMed ID: 12417730
[TBL] [Abstract][Full Text] [Related]
10. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates.
Adya N; Stacy T; Speck NA; Liu PP
Mol Cell Biol; 1998 Dec; 18(12):7432-43. PubMed ID: 9819429
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.
Wichmann C; Grez M; Lausen J
Curr Drug Targets; 2010 Sep; 11(9):1181-91. PubMed ID: 20583973
[TBL] [Abstract][Full Text] [Related]
12. Core binding factor beta-smooth muscle myosin heavy chain chimeric protein involved in acute myeloid leukemia forms unusual nuclear rod-like structures in transformed NIH 3T3 cells.
Wijmenga C; Gregory PE; Hajra A; Schröck E; Ried T; Eils R; Liu PP; Collins FS
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1630-5. PubMed ID: 8643682
[TBL] [Abstract][Full Text] [Related]
13. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta.
Tahirov TH; Inoue-Bungo T; Morii H; Fujikawa A; Sasaki M; Kimura K; Shiina M; Sato K; Kumasaka T; Yamamoto M; Ishii S; Ogata K
Cell; 2001 Mar; 104(5):755-67. PubMed ID: 11257229
[TBL] [Abstract][Full Text] [Related]
14. Filamin A-bound PEBP2beta/CBFbeta is retained in the cytoplasm and prevented from functioning as a partner of the Runx1 transcription factor.
Yoshida N; Ogata T; Tanabe K; Li S; Nakazato M; Kohu K; Takafuta T; Shapiro S; Ohta Y; Satake M; Watanabe T
Mol Cell Biol; 2005 Feb; 25(3):1003-12. PubMed ID: 15657428
[TBL] [Abstract][Full Text] [Related]
15. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.
Michaud J; Wu F; Osato M; Cottles GM; Yanagida M; Asou N; Shigesada K; Ito Y; Benson KF; Raskind WH; Rossier C; Antonarakis SE; Israels S; McNicol A; Weiss H; Horwitz M; Scott HS
Blood; 2002 Feb; 99(4):1364-72. PubMed ID: 11830488
[TBL] [Abstract][Full Text] [Related]
16. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.
Barseguian K; Lutterbach B; Hiebert SW; Nickerson J; Lian JB; Stein JL; van Wijnen AJ; Stein GS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15434-9. PubMed ID: 12427969
[TBL] [Abstract][Full Text] [Related]
17. The RUNX1 Runt domain at 1.25A resolution: a structural switch and specifically bound chloride ions modulate DNA binding.
Bäckström S; Wolf-Watz M; Grundström C; Härd T; Grundström T; Sauer UH
J Mol Biol; 2002 Sep; 322(2):259-72. PubMed ID: 12217689
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of transcriptional repression by TEL/RUNX1 fusion protein.
Lee YJ; Kim JH; Bae S; Rho SK; Choe SY
Mol Cells; 2004 Apr; 17(2):217-22. PubMed ID: 15179033
[TBL] [Abstract][Full Text] [Related]
19. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
20. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
Richter LE; Wang Y; Becker ME; Coburn RA; Williams JT; Amador C; Hyde RK
Mol Cancer Res; 2019 Jun; 17(6):1241-1252. PubMed ID: 30814129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]